Literature DB >> 17954912

Murine models of acute neuronopathic Gaucher disease.

Ida Berglin Enquist1, Christophe Lo Bianco, Andreas Ooka, Eva Nilsson, Jan-Eric Månsson, Mats Ehinger, Johan Richter, Roscoe O Brady, Deniz Kirik, Stefan Karlsson.   

Abstract

Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the glucosidase, beta, acid (GBA) gene that encodes the lysosomal enzyme glucosylceramidase (GCase). GCase deficiency leads to characteristic visceral pathology and, in some patients, lethal neurological manifestations. Here, we report the generation of mouse models with the severe neuronopathic form of GD. To circumvent the lethal skin phenotype observed in several of the previous GCase-deficient animals, we genetically engineered a mouse model with strong reduction in GCase activity in all tissues except the skin. These mice exhibit rapid motor dysfunction associated with severe neurodegeneration and apoptotic cell death within the brain, reminiscent of neuronopathic GD. In addition, we have created a second mouse model, in which GCase deficiency is restricted to neural and glial cell progenitors and progeny. These mice develop similar pathology as the first mouse model, but with a delayed onset and slower disease progression, which indicates that GCase deficiency within microglial cells that are of hematopoietic origin is not the primary determinant of the CNS pathology. These findings also demonstrate that normal microglial cells cannot rescue this neurodegenerative disease. These mouse models have significant implications for the development of therapy for patients with neuronopathic GD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17954912      PMCID: PMC2077282          DOI: 10.1073/pnas.0708086104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease.

Authors:  R O Brady; J N Kanfer; R M Bradley; D Shapiro
Journal:  J Clin Invest       Date:  1966-07       Impact factor: 14.808

2.  Acute infantile Gaucher's disease in identical twins. An account of clinical and neuropathologic observations.

Authors:  O E Espinas; A A Faris
Journal:  Neurology       Date:  1969-02       Impact factor: 9.910

3.  Fine structure of central nervous system in early infantile Gaucher's disease.

Authors:  M Adachi; B J Wallace; L Schneck; B W Volk
Journal:  Arch Pathol       Date:  1967-06

4.  Efficient three-drug cocktail for disease induced by mutant superoxide dismutase.

Authors:  Jasna Kriz; Geneviève Gowing; Jean-Pierre Julien
Journal:  Ann Neurol       Date:  2003-04       Impact factor: 10.422

5.  Disruption of neural signal transducer and activator of transcription 3 causes obesity, diabetes, infertility, and thermal dysregulation.

Authors:  Qian Gao; Michael J Wolfgang; Susanne Neschen; Katsutaro Morino; Tamas L Horvath; Gerald I Shulman; Xin-Yuan Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-22       Impact factor: 11.205

6.  Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3.

Authors:  U H Schueler; T Kolter; C R Kaneski; J K Blusztajn; M Herkenham; K Sandhoff; R O Brady
Journal:  Neurobiol Dis       Date:  2003-12       Impact factor: 5.996

7.  Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.

Authors:  You-Hai Xu; Brian Quinn; David Witte; Gregory A Grabowski
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

8.  Neuropathology provides clues to the pathophysiology of Gaucher disease.

Authors:  Kondi Wong; Ellen Sidransky; Ajay Verma; Tonghui Mixon; Glenn D Sandberg; Laura K Wakefield; Alan Morrison; Alicia Lwin; Carlos Colegial; John M Allman; Raphael Schiffmann
Journal:  Mol Genet Metab       Date:  2004-07       Impact factor: 4.797

9.  Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis.

Authors:  Jasna Kriz; Minh Dang Nguyen; Jean-Pierre Julien
Journal:  Neurobiol Dis       Date:  2002-08       Impact factor: 5.996

10.  Hematopoietic origin of microglial and perivascular cells in brain.

Authors:  David C Hess; Takanori Abe; William D Hill; Angeline Martin Studdard; Jo Carothers; Masahiro Masuya; Paul A Fleming; Christopher J Drake; Makio Ogawa
Journal:  Exp Neurol       Date:  2004-04       Impact factor: 5.330

View more
  73 in total

1.  Neonatal Bone Marrow Transplantation in MPS IIIA Mice.

Authors:  Adeline A Lau; N Jannah Shamsani; Leanne K Winner; Sofia Hassiotis; Barbara M King; John J Hopwood; Kim M Hemsley
Journal:  JIMD Rep       Date:  2012-08-10

Review 2.  Astrocytes and lysosomal storage diseases.

Authors:  K V Rama Rao; T Kielian
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

3.  CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy.

Authors:  S Pablo Sardi; Jennifer Clarke; Cathrine Kinnecom; Thomas J Tamsett; Lingyun Li; Lisa M Stanek; Marco A Passini; Gregory A Grabowski; Michael G Schlossmacher; Richard L Sidman; Seng H Cheng; Lamya S Shihabuddin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-05       Impact factor: 11.205

4.  Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.

Authors:  Yumiko V Taguchi; Jun Liu; Jiapeng Ruan; Joshua Pacheco; Xiaokui Zhang; Justin Abbasi; Joan Keutzer; Pramod K Mistry; Sreeganga S Chandra
Journal:  J Neurosci       Date:  2017-08-28       Impact factor: 6.167

Review 5.  Lysosomal storage diseases.

Authors:  Frances M Platt; Alessandra d'Azzo; Beverly L Davidson; Elizabeth F Neufeld; Cynthia J Tifft
Journal:  Nat Rev Dis Primers       Date:  2018-10-01       Impact factor: 52.329

Review 6.  Lysosomal impairment in Parkinson's disease.

Authors:  Benjamin Dehay; Marta Martinez-Vicente; Guy A Caldwell; Kim A Caldwell; Zhenyue Yue; Mark R Cookson; Christine Klein; Miquel Vila; Erwan Bezard
Journal:  Mov Disord       Date:  2013-04-11       Impact factor: 10.338

7.  Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).

Authors:  Megan E Bosch; Amy Aldrich; Rachel Fallet; Jessica Odvody; Maria Burkovetskaya; Kaitlyn Schuberth; Julie A Fitzgerald; Kevin D Foust; Tammy Kielian
Journal:  J Neurosci       Date:  2016-09-14       Impact factor: 6.167

8.  Increased glucocerebrosidase (GBA) 2 activity in GBA1 deficient mice brains and in Gaucher leucocytes.

Authors:  Derek G Burke; Ahad A Rahim; Simon N Waddington; Stefan Karlsson; Ida Enquist; Kailash Bhatia; Atul Mehta; Ashok Vellodi; Simon Heales
Journal:  J Inherit Metab Dis       Date:  2012-11-15       Impact factor: 4.982

9.  Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.

Authors:  Ying Sun; Benjamin Liou; Huimin Ran; Matthew R Skelton; Michael T Williams; Charles V Vorhees; Kazuyuki Kitatani; Yusuf A Hannun; David P Witte; You-Hai Xu; Gregory A Grabowski
Journal:  Hum Mol Genet       Date:  2010-01-04       Impact factor: 6.150

10.  In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models.

Authors:  Ying Sun; Benjamin Liou; Brian Quinn; Huimin Ran; You-Hai Xu; Gregory A Grabowski
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.